This study is currently not recruiting participants.

Protein and Energy Metabolism in Pediatric Crohn's

Study on Effects of Investigational Medication or Steroids on Body Functions

Not Recruiting
6 years - 18 years
All
Phase N/A

Brief description of study.

The purpose of this study is to determine the effects of infliximab or steroids on protein and lipid use, and energy expenditure.

Detailed description of study

The purpose of this study is to determine the effects of infliximab or steroids on protein and lipid use, and energy expenditure.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Crohn's disease
  • Age: 6 years - 18 years
  • Gender: All

The purpose of this study is to determine the effects of investigational medication or steroids on how the body uses proteins and fats, and on energy expenditure. Energy expenditure refers to the amount of energy a person uses to maintain basic body functions and perform physical activities.

Participants in this study will receive either the investigational medication or steroids. The study will monitor how these treatments affect the body's use of proteins and lipids, as well as energy expenditure. This will involve measuring these factors under controlled conditions.

  • Who can participate: Eligible participants are adults aged 18 to 65 who are generally healthy. Key eligibility factors include no history of metabolic disorders and not currently taking medications that affect metabolism.
  • Study details: Participants will receive either the investigational medication or steroids to assess their effects on protein and lipid use and energy expenditure. A placebo, which is an inactive substance that looks like the investigational medication but does not contain any medicine, may also be used.
Updated on 19 Feb 2024. Study ID: 1011003125 (0506-19)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team